The U.S. Attorney General’s office says it is reviewing an open letter submitted by a consumer group encouraging a criminal probe into the destruction by Johnson & Johnson (J&J) of pelvic mesh litigation documents. That announcement comes after Corporate Action Network (CAN) asked Eric Holder Jr. to explore how and […]
Yesterday afternoon, Congress’s Subcommittee on Health held a hearing to examine the FDA’s proposal to change the rules of generic drug labeling. Under the current law, enacted in 1984, warning labels for particular drug formulations are created by the brand-name manufacturers, and generic manufacturers are legally prevented from altering them. […]
When the mercury-based preservative thimerosol was slowly removed from childhood vaccines it was assumed that the astonishing rates of autism would decline. Autism is a brain abnormalty that makes children socially awkward if not totally withdrawn. For years it was suspected that mercury toxicity was behind cases of autism, estimated […]
Johnson and Johnson (J&J) and its subsidiary Janssen Pharmaceuticals have been dealing with multiple lawsuits stemming from its drug Risperdal. Shortly after dodging a $1.2 billion judgment in Arkansas, J&J has returned its focus to the multidistrict litigation (MDL) currently pending in Pennsylvania. The company is now trying to shield […]
The Wall Street Journal reports on conflict of interest disclosures that have evolved as a result of transvaginal mesh (TVM) lawsuits filed against healthcare giant, Ethicon, a division of Johnson & Johnson. Amid the hundreds of thousands of pages of documents provided in the 17,000 cases filed in federal court […]
Two years ago, healthcare giant Johnson & Johnson was facing a $1.2 billion judgment after a jury determined J&J concealed the risks of its antipsychotic drug Risperdal while it aggressively and improperly marketed it off-label. At the time it was the largest state fine over the mismarketing of Risperdal and […]
Congratulations, Brenda! We’ve reprinted the article below. Reprinted with permission of Trial (March 2014) Copyright American Association for Justice, formerly Association of Trial Lawyers of America (ATLA®) Gender equity in the law March 2014, Volume 50, No. 3 Sidebar: Brenda Fulmer: Working hard and staying true Courtney L. Davenport When […]
Doctors and physicians are given a great deal of discretion when it comes to prescribing drugs for uses other than those indicated by the FDA. This is known as “off-label” use. The FDA, realizing the danger of off-label promotion in its 2009 guidance, has set forth rules to restrict the […]
While it is not official, Bloomberg is reporting that Coloplast A/S, one of the smaller manufacturers of transvaginal meshes, is said to be willing to settle a number of lawsuits for $16 million. Three different individuals tipped the news outlet, but none were reportedly authorized to speak. The Danish company […]
A federal report issued by the Centers for Disease Control and Prevention (CDC) indicates that extensive prescribing of antibiotics is at least partially responsible for the development of C. diff (Clostridium difficile), an antibiotic-resistant bacterial infection also known as a superbug. C. diff infections affect about 250,000 patients every year […]
